UNION-ViPS-C2401022
The cell line is not validated yet.
UNIONi001-A
General
Cell Line |
|
| hPSCreg name | UNIONi001-A |
| Cite as: | UNIONi001-A |
| Alternative name(s) |
UNION-ViPS-C2401022
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 9th April 2025 |
| User feedback | |
Provider |
|
| Generator | UNION STEM CELL & GENE ENGINEERING CO., LTD. (UNION) |
| Owner | UNION STEM CELL & GENE ENGINEERING CO., LTD. (UNION) |
| Derivation country | China |
External Databases |
|
| BioSamples | SAMEA117847999 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA117848036 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
The blood from the umbilical cord of a newborn baby contains high concentrations of stem cells (cells from which all blood cells develop).
|
| Source cell origin |
Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of hematopoietic progenitor cells for transplantation to a patient later diagnosed and treated for a hematopoietic disorder.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
Yes |
| Available as clinical grade? |
Yes |
Culture Conditions
| Feeder cells |
No |
| Passage method | Enzyme-free cell dissociation |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|
||
| SOX2 |
Yes |
|
|
|
||
| SSEA-4 |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|
Morphology pictures
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XY
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.